Eighth Annual BIO Investor Forum to Feature Distinguished Clinical Investigators and Industry Executives
“Once again, the BIO Investor Forum will offer insightful and timely discussions on therapeutic innovation and competition in the biotech industry that are of keen interest to investors and industry,” said Jim Greenwood, president and CEO of BIO. “BIO is committed to providing high-quality, independent forums where clinicians, investigators and industry leaders can examine topics that will benefit the entire biotechnology community and ultimately the patients and consumers we serve.”
This year, BIO is collaborating with Panel Intelligence (formerly MedPanel), a healthcare market research firm, to identify key opinion leaders based upon their knowledge and expertise in their respective fields and affiliations with prestigious academic institutions and medical foundations.
“By establishing a partnership with Panel Intelligence, BIO can easily access clinical thought leaders qualified to provide seasoned perspectives to this year’s therapeutic panel discussions,” said Greenwood.
“We are honored to sponsor the leading clinicians and investigators participating in the Eighth Annual BIO Investor Forum Therapeutic Workshops – an innovative discussion format where clinical thought leaders, industry executives and investors bring their insights together around a focused development area,” said Will Febbo, Chief Executive Officer of Panel Intelligence. “We hope our work with BIO and 10 years of experience connecting leading medical experts with the biotechnology industry and investors will bring significant value for attendees.”
Clinical thought leaders, leading company executives, analysts and patient advocacy experts featured on panels at the Eighth Annual BIO Investor Forum include:
Pipelines with Promise—A Focus on Emerging Prostate Cancer Treatments
Wednesday, October 28, 9:30am - 10:45am
-
Martin Gleave, MD, FRCSC, FACS, Chief Scientific Officer, OncoGenex Pharmaceuticals, Inc.
-
Mitchell H. Gold, MD, Chief Executive Officer, Dendreon Corporation
-
Charles J. Ryan, MD, Associate Professor of Clinical Medicine - Division of Hematology/Oncology, University of California, San Francisco
-
Howard R. Soule, PhD, Executive Vice President and Chief Science Officer, Prostate Cancer Foundation
Predicting a Frontrunner in the Race Against Pandemic Flu
Thursday, October 29, 8:00am - 9:15am
-
Tomas Aragon, M.D., DrPH, Executive director of UC Berkeley's Center for Infectious Disease Preparedness Expertise
-
J. Joseph Kim, PhD, Chief Executive Officer, Inovio Biomedical Corporation
-
Rahul Singhvi, ScD, MBA, President and Chief Executive Officer, Novavax, Inc.
Making it Personal - Transforming Patient Outcomes and Narrowing Development Risk
Thursday, October 29, 2009, 11:00am - 12:15pm
-
Alessandra Cesano, MD, Ph.D, Chief Medical Officer, Nodality, Inc.
-
Todd Klinger, PhD Vice President of Information Sciences, XDx, Inc.
-
Ronald W. Lennox, D Phil, Partner, CHL Medical PartnersPamela Munster, MD, Associate Professor of Medicine - Division of Hematology/Oncology, University of California, San Francisco
Resisting the Enemy Within - Keeping Score on the War Against Autoimmune Disease
Thursday, October 29, 2009, 2:00pm - 3:00pm
-
C. Garrison Fathman, MD, Chief Division of Immunology and Rheumatology, Stanford University School of Medicine
-
John A. Hardin, MD, Chief Scientific Officer, Arthritis Foundation
-
Sandra C. Raymond, President and Chief Executive Officer, Lupus Foundation of America
-
Patrick J. Scannon, MD, PhD, Executive Vice President and Chief Scientific Officer, XOMA Ltd.
To register to attend the BIO Investor Forum, please visit http://investorforum.bio.org/. Registration is complimentary for qualified investors and credentialed members of the media.
Private and public biopharmaceutical companies interested in presenting at the conference are encouraged to apply online at http://investorforum.bio.org/bif/2009/presentations/presentationapp.asp.
Media are asked to advance register at http://investorforum.bio.org/opencms/bif/2009/media/.
The BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
About Panel Intelligence
Panel Intelligence, formerly MedPanel, Inc., is proud to be working with BIO to provide leading industry experts on these therapeutic workshops. As a fully committed and capable research partner, Panel Intelligence works closely with BIO to identify objectives, recruit experts, elicit information, and synthesize results. Panel Intelligence's domain expertise, global network of experts, and proven online methods can provide due diligence on one particular company, investigate a particular space, evaluate an IPO, or identify market trends and consumer preferences.
Upcoming BIO Events
BIO Investor Forum
October 28-29, 2009
San Francisco, CA
Advanced Business Development Course
October 30, 2009
Vienna, Austria
BIO Europe International Partnering Conference
November 2-4, 2009
Vienna, Austria
Pacific Rim Summit on Industrial Biotechnology and Bioenergy
November 8-11, 2009
Honolulu, HI
BIO Asia Partnering Conference
January 25-26
Tokyo, Japan
BIO CEO & Investor Conference
February 8-9, 2010
New York, NY
###